⌕
Avalyn Pharma · AVLN · Nasdaq
Tenet — · insufficient data
Compare
$27.92−6.18%At close
$27.92−1.84 (−6.18%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
Data under review. Our nightly checks found a problem in this company's reported figures on Oct 23, 2026, so we are not showing its score, ratios or statements for now. The figures come back after they pass the checks two nights in a row. The price and chart are live.

Avalyn Pharma (AVLN) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is AVLN's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Seeking AlphaNov 11, 2026 · 16:29 ET
Avalyn Pharma Inc. (AVLN) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript

Avalyn Pharma Inc. (AVLN) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript…

AVLN −6.2% todayRead at source ↗
● GlobeNewsWireNov 3, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Avalyn to Present at Upcoming Investor Conferences

BOSTON, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseas…

AVLN −6.2% todayRead at source ↗
● Defense WorldOct 1, 2026 · 06:15 ET
Avalyn Pharma Inc. (NASDAQ:AVLN) Stock Now Rated “Moderate Buy” by Wall Street Analysts

Avalyn Pharma Inc. (NASDAQ: AVLN - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the six research firms that are presently covering the company, MarketBeat reports. One equities research a…

AVLN −6.2% todayRead at source ↗
● GlobeNewsWireSep 21, 2026 · 09:00 ETCOMPANY'S OWN WORDS
Avalyn Publishes Phase 1 Data Highlighting AP02's Lung-Targeted Delivery and Encouraging Safety Profile

Results validate Avalyn's approach of delivering established antifibrotic medicines directly to the lungs to maximize local exposure while limiting systemic exposure and improving tolerability…

AVLN −6.2% todayRead at source ↗
● GlobeNewsWireSep 16, 2026 · 16:01 ETCOMPANY'S OWN WORDS
Avalyn Appoints Robert J. Meyer, MD, to its Board of Directors

BOSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN) (“Avalyn” or the “Company”), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of ser…

AVLN −6.2% todayRead at source ↗
● Seeking AlphaSep 14, 2026 · 16:41 ET
Avalyn Pharma Inc. (AVLN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Avalyn Pharma Inc. (AVLN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript…

AVLN −6.2% todayRead at source ↗
● GlobeNewsWireSep 8, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Avalyn Presents New Data at ERS Congress 2026 Supporting AP01 Lung Distribution and Patient-Centered Trial Design in Pulmonary Fibrosis

In silico modeling predicts robust AP01 distribution in healthy and fibrotic lungs, even in severe disease Patient survey findings suggest that clear communication, transparent discussions of potential benefits and risks…

AVLN −6.2% todayRead at source ↗
● GlobeNewsWireSep 8, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Avalyn to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory disea…

AVLN −6.2% todayRead at source ↗
● GlobeNewsWireAug 24, 2026 · 16:01 ETCOMPANY'S OWN WORDS
Avalyn Announces Multiple Presentations at the European Respiratory Society International Congress 2026

Presentations describe integration of patient perspective into clinical trial design and data modeling AP01 distribution in the lungs Presentations describe integration of patient perspective into clinical trial design a…

AVLN −6.2% todayRead at source ↗

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

NVDA31−0.4%
WDAY4−5.8%
EG3−2.0%

Article counts from the last market-wide feed page, across every symbol we track and not just AVLN · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.